HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

dimethylenastron

a kinesin Eg5 inhibitor and antiproliferative agent; structure in first source

Also Known As:

DMEN enastron

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - dimethylenastron: 5
Inorganic Chemicals: 9
- Thiones: 70
  - dimethylenastron: 5
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiones: 70
    - dimethylenastron: 5

Experts

1.	Giannis, Athanassios: 2 articles (12/2010 - 02/2007)
2.	Sun, Linlin: 1 article (05/2014)
3.	Sun, Xiaodong: 1 article (05/2014)
4.	Xie, Songbo: 1 article (05/2014)
5.	Yu, Haiyang: 1 article (05/2014)
6.	Zhong, Diansheng: 1 article (05/2014)
7.	Li, Deng-wen: 1 article (12/2011)
8.	Liu, Min: 1 article (12/2011)
9.	Luo, You-guang: 1 article (12/2011)
10.	Shi, Xing-juan: 1 article (12/2011)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 12/01/2011 - "This study was undertaken to investigate the effect of dimethylenastron, a specific inhibitor of Eg5, on the migration and invasion of pancreatic cancer cells. " 12/01/2011 - "Dimethylenastron inhibits the migration and invasion of PANC1 pancreatic cancer cells, independent of suppressing the cell proliferation. " 12/01/2011 - "Treatment of PANC1 pancreatic cancer cells with dimethylenastron (3 and 10 μmol/L) for 24 h suppressed the migratory ability of the cancer cells in a concentration-dependent manner. " 12/01/2011 - "Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5."
2.	Neoplasms (Cancer) 12/01/2011 - "However, treatment of PANC1 cells with dimethylenastron (3 and 10 μmol/L) for 24 h had no detectable effect on their proliferation, which was inhibited when the cancer cells were treated with the drug for 72 h. " 12/01/2011 - "Treatment of PANC1 pancreatic cancer cells with dimethylenastron (3 and 10 μmol/L) for 24 h suppressed the migratory ability of the cancer cells in a concentration-dependent manner. " 05/09/2014 - "Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation." 04/01/2009 - "Here, we show that targeting the mitotic kinesin Eg5 (also known as kinesin spindle protein, KSP) by a small interfering RNA (siRNA) or by the pharmacological inhibitor dimethylenastron (DIMEN) kills tetraploid tumor cells more efficiently than their diploid precursors. "
3.	Tetraploidy 04/01/2009 - "Here, we show that targeting the mitotic kinesin Eg5 (also known as kinesin spindle protein, KSP) by a small interfering RNA (siRNA) or by the pharmacological inhibitor dimethylenastron (DIMEN) kills tetraploid tumor cells more efficiently than their diploid precursors. "
4.	Lung Neoplasms (Lung Cancer) 05/09/2014 - "By comparing with enastron, here we report that dimethylenastron prevents the growth of pancreatic and lung cancer cells more effectively, by halting mitotic progression and triggering apoptosis. "
5.	Inflammation (Inflammations) 12/01/2010 - "Except for two cases of transient fibrinous reaction after the injection of 3.0 µmol Dimethylenastron, no adverse effects, such as inflammation or blurring of the optical media, were observed. "

Related Drugs and Biologics

1.	Kinesins
2.	enastron
3.	Small Interfering RNA (siRNA)
4.	Proteins (Proteins, Gene)
5.	Gentian Violet (Violet, Crystal)
6.	Dimethyl Sulfoxide (DMSO)
7.	Adenosine Diphosphate (ADP)
8.	vasastrol VS-83
9.	monastrol

Related Therapies and Procedures

1.	Filtering Surgery